| 8:30 AM - 10:00 AM | BASIC PARALLEL 1 - HCV virology: replicating success - What can we learn from HCV for the other hepatitis viruses? Ralf Bartenschlager
- Pharmacology of long-acting HCV therapeutics Andrew Owen
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
| CLINICAL PARALLEL 2 - Practical Strategies for implementing Guidelines and Maximizing Treatment Outcomes - How to Engage and Support Priority Populations for Viral Hepatitis Care in Non-Endemic Regions Christine Greenway
- Development and Expansion of Novel Care Models for a Global Population
- Patient and Provider Perspective on Overcoming Barriers to Care Su Wang
- Oral Presentation
- Oral Presentation
- Q&A
| CLINICAL PARALLEL 1 - Management of HBV in 2025 - Interferon as a Component of HBV Cure in 2024 and 2034 Harry Janssen
- Invited Talk
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
|
| 10:30 AM - 12:00 PM | PLENARY 2 - State of the Art: Report Card on Drug Development for HBV: Lessons Learned and the Path Forward - Report Card on Drug Development for HBV: Lessons Learned and the Path Forward + Q&A Ed Gane
- Oral Presentation + Q&A
- Oral Presentation + Q&A
- Introductory Talk
- Panel - HBV Theraputics (what's needed now and in the future) + Q&A
|
| 1:30 PM - 3:00 PM | CLINICAL PARALLEL 3 - ILCA-GHS HCC Symposium - Risk stratification – HBV and post-SVR
- Debate – Are there patients that we can stop surveillance in low risk patients? Neil Mehta
- Early detection/screening – surveillance underuse and emerging modalities Ju Dong Yang
- Panel – implementation of these strategies Neil Mehta; Ju Dong Yang
| BASIC PARALLEL 2 - MishMASH: molecular mechanisms for liver disease - MASH: molecular underpinnings of novel therapeutics Percy Knolle
- Inflammatory premise for cancer
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
|
| 3:30 PM - 5:00 PM | CLINICAL PARALLEL 5 - Delta Therapies -- Current and Future - Overview of New Drug Development for Hepatitis Delta
- Bulevirtide (BLV) as Monotherapy or Combination Treatment with Interferon for Hepatitis Delta Maria Buti
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
| CLINICAL PARALLEL 4 - Optimizing HBV Treatment: Propsects for a functional cure - Progress towards a Sterilizing Cure - Advances in Gene editing and Targeting cccDNA Fabien Zoulim
- The Role of RNA interference (siRNA, ASO) as the backbone of HBV Cure strategies Kosh Agarwal
- Invited Talk
- Oral Presentation
- Oral Presentation
- Q&A
|
| 8:30 AM - 10:00 AM | BASIC PARALLEL 3 - "Dueling" virology: HBV and HDV - Molecular basis for an HBV cure using antivirals Chloe Thio
- From controlling HDV to HDV cure Marc Ghany
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
| CLINICAL PARALLEL 6 - HBV Treatment Challenges and Controversies - Do Not Stop Long-Term NA Therapy in Absence of Functional Cure (against) Anna Lok
- You Can Stop Long-Term Therapy in Absence of Functional Cure (for)
- What is the Evidence for Expanding NA Therapy Patrick Kennedy
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
|
| 10:30 AM - 12:00 PM | PLENARY 3 - State of the Art: Thinking outside the Box for HCV: Treat to Cure and Eliminate - Thinking outside the Box for HCV: Treat to Cure and Eliminate + Q&A Margaret Hellard
- Oral Presentation + Q&A
- Oral Presentation + Q&A
- Introductory Talk
- Panel + Q&A
|
| 1:30 PM - 3:00 PM | BASIC PARALLEL 4 - Exploiting adaptive immunity to combat viral hepatitis - Restoring immunity to cure hepatitis B Ulrike Protzer
- Immunologic prescription for a vaccine to prevent chronic hepatitis C Andrea Cox
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
| CLINICAL PARALLEL 7 - New Diagnostics and Technologies in Liver Disease - Potential for Current and Future Clinical Practice - Novel Biomarkers and Point of Care Tests for HBV management
- Application of Artifical Intelligence in Viral Hepatitis
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
|
| 3:30 PM - 5:00 PM | CLINICAL PARALLEL 8 - Overlapping Epidemics: Viral Hepatitis Meets Steatotic Liver Disease - Alcohol and Viral Hepatitis: How Much is too Much? Jennifer Flemming
- Risk of HCC in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Viral Hepatitis
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
|
| 3:30 PM - 5:30 PM | CLINICAL PARALLEL 9 - Remaining Challenges in Hepatitis C - HCV : Improving care after HCV diagnosis and after HCV Cure Jennifer Price
- Treatment of HCV in Context of HCC - Remaining Challenges in 2025
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A
|
